Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. (RDTCF) Financial Performance & Income Statement Overview
Review Rapid Dose Therapeutics Corp. (RDTCF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Rapid Dose Therapeutics Corp. (RDTCF) Income Statement & Financial Overview
Explore comprehensive income reports for Rapid Dose Therapeutics Corp. RDTCF, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $668577.00 | $501689.00 | $515916.00 | $398994.00 |
| Cost of Revenue | $343552.00 | $231355.00 | $187920.00 | $1.009M |
| Gross Profit | $325025.00 | $270334.00 | $327996.00 | $256704.00 |
| Gross Profit Ratio | $0.49 | $0.54 | $0.64 | $0.64 |
| R&D Expenses | $48624.00 | $44086.00 | $26019.00 | $29516.00 |
| SG&A Expenses | $1.56M | $1.20M | $1.11M | $1.10M |
| Operating Expenses | $1.67M | $1.29M | $1.19M | $1.21M |
| Total Costs & Expenses | $2.01M | $1.52M | $1.37M | $1.35M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $338472.00 | $347755.00 | $242146.00 | $304033.00 |
| Depreciation & Amortization | $59646.00 | $48160.00 | $50215.00 | $82733.00 |
| EBITDA | -$1.28M | -$969000.00 | -$807000.00 | -$872000.00 |
| EBITDA Ratio | -$1.92 | -$1.93 | -$1.56 | -$2.19 |
| Operating Income | -$1.34M | -$1.02M | -$807298.00 | -$872000.00 |
| Operating Income Ratio | -$2.009 | -$2.03 | -$1.56 | -$2.19 |
| Other Income/Expenses (Net) | -$338472.00 | -$348000.00 | -$242000.00 | -$304000.00 |
| Income Before Tax | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Income Before Tax Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.00 |
| Net Income | -$1.68M | -$1.36M | -$1.10M | -$1.26M |
| Net Income Ratio | -$2.52 | -$2.72 | -$2.13 | -$3.15 |
| EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Diluted EPS | -$0.01 | -$0.01 | -$0.009 | -$0.01 |
| Weighted Avg Shares Outstanding | $129.53M | $124.17M | $123.12M | $121.76M |
| Weighted Avg Shares Outstanding (Diluted) | $129.53M | $124.17M | $123.12M | $121.76M |
The company's financials show resilient growth, with revenue advancing from $398994.00 in Q1 2024 to $668577.00 in Q4 2024. Gross profit remained healthy with margins at 49% in Q4 2024 compared to 64% in Q1 2024. Operating income hit -$1.34M last quarter, sustaining a consistent -201% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.28M. Net income dropped to -$1.68M, while earnings per share reached -$0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan